The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.
The use of steroids in septic shock remains controversial. The purpose of this study is to determine whether hydrocortisone decreases 28-day mortality in patients with septic shock. The primary end point will be 28-day mortality in all the non-responders to ACTH (\< or = 9 mcg/dl or 250 nmol/L post ACTH). Secondary endpoints will be 28 day all cause mortality in the total group and in responders, ICU and hospital mortality, one year mortality, organ system failure reversal especially shock, and duration of ICU and total hospitalisation. In a double-blinded fashion (randomized on a 1:1 basis), patients receive 50 mg intravenously every 6 hours for 5 days. After 5 days, treatment will be tapered with 50 mg given intravenously every 12 hours for days 6-8, then 50 mg every 24 hours for days 9-11, and then stopped. All concomitant treatments, including antibiotics, fluids, vasopressors and ancillary therapies will be given at the discretion of the primary care physician. Evidence-based guidelines for the management of severe sepsis and septic shock by the International Sepsis Forum (Intensive Care Med 2001;27:S124-S134) are encouraged to be followed. All serious adverse events (SAE) which occur between days 0 and 28, which are unexpected and/or considered possibly or probably related to the study medication, must be documented and reported within 24 hours to the Safety and Efficacy Monitoring Committee. Non-serious adverse events will be listed on the case report form if they are unexpected and believed to be related to the study drug during days 0 to 14. Specific adverse events which will be monitored closely because of their relationship to corticosteroids and shock are: 1. Use of corticosteroids, i.e. gastrointestinal bleeding and superinfection; hyperglycemia, hypernatremia, muscular weakness, etc. 2. Shock and use of vasopressors, i.e. stroke, acute myocardial infarction and peripheral ischemia. In addition, substudies will include harmonization of cortisol by comparing cortisol levels measured in local laboratories and a central laboratory, immune and neuro-endocrine interactions, neuromuscular weakness and cytokines.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
500
50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
28 day mortality in all the non-responders to ACTH (< or = 9 mcg/dl or 250 nmol/L post ACTH)
Time frame: 28 days
28 day all cause mortality in the total group.
Time frame: 28 days
28 day all cause mortality in responders.
Time frame: 28 days
One year mortality in nonresponders, total and responders.
Time frame: one year
ICU and hospital mortality.
Time frame: one year
Organ system failure reversal, especially shock.
Time frame: one year
Duration of ICU and total hospitalisation.
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
LKH Feldkirch
Feldkirch, Austria
KH-BHS Linz
Linz, Austria
Krankenhaus der Barmherzigen Schwestern Ges. mbH
Linz, Austria
Universitaetsklinik fuer Innere Medizin II
Vienna, Austria
Hopital St. Joseph
Arlon, Belgium
University Hospital Erasme
Brussels, Belgium
Cliniques Universitaires St. Luc, UCL
Brussels, Belgium
CHU Charleroi
Charleroi, Belgium
Hopital Raymond Poincare
Paris, Garches, France
Hopital Lariboisiere
Paris, Oarus, France
...and 47 more locations